Hangzhou Center for Disease Control and Prevention, Hangzhou, 310021, China.
Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, 310051, China.
BMC Infect Dis. 2021 Aug 21;21(1):853. doi: 10.1186/s12879-021-06579-6.
Malaria causes major public health problems globally and drug resistance hinders its control and elimination. Molecular markers associated with drug resistance are considered as a beneficial tool to monitor the disease trends, evolution and distribution so as to help improve drug policy.
We collected 148 Plasmodium falciparum and 20 Plasmodium vivax isolates imported into Hangzhou city, China between 2014 and 2019. k13 gene of P. falciparum and k12 of P. vivax were sequenced. Polymorphisms and prevalence of k13 and k12 were analyzed.
Most (98.65%, 146/148) P. falciparum infections were imported from Africa, and half P. vivax cases came from Africa and the other half from Asia. Nucleotide mutation prevalence was 2.03% (3/148) and the proportion of amino acid mutations was 0.68% (1/148). The amino acid mutation, A676S, was observed in an isolate from Nigeria. No mutation of k12 was observed from the parasites from African and Asian countries.
Limited polymorphism in k13 gene of P. falciparum isolates imported from African countries, but no evidence for the polymorphism of k12 in P. vivax samples from African and Asian countries was found. These results provide information for drug policy update in study region.
疟疾在全球范围内造成重大公共卫生问题,药物耐药性阻碍了其控制和消除。与耐药性相关的分子标志物被认为是监测疾病趋势、演变和分布的有益工具,有助于改善药物政策。
我们收集了 2014 年至 2019 年间输入中国杭州市的 148 株恶性疟原虫和 20 株间日疟原虫。对恶性疟原虫的 k13 基因和间日疟原虫的 k12 进行了测序。分析了 k13 和 k12 的多态性和流行率。
大多数(98.65%,146/148)恶性疟原虫感染来自非洲,一半间日疟原虫病例来自非洲,另一半来自亚洲。核苷酸突变率为 2.03%(3/148),氨基酸突变率为 0.68%(1/148)。在来自尼日利亚的一个分离株中观察到 A676S 氨基酸突变。来自非洲和亚洲国家的寄生虫未观察到 k12 的突变。
从非洲国家输入的恶性疟原虫分离株 k13 基因的多态性有限,但未发现非洲和亚洲国家间日疟原虫样本 k12 的多态性证据。这些结果为研究区域的药物政策更新提供了信息。